Monte Rosa Therapeutics (GLUE) EBIT (2020 - 2026)
Monte Rosa Therapeutics (GLUE) recorded quarterly EBIT of -$50.0 million in Q1 2026, down 1211.51% quarter-over-quarter from -$3.8 million in Q4 2025, and down 213.62% on a YoY basis from $44.0 million in Q1 2025.
Monte Rosa Therapeutics (GLUE) EBIT (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' EBIT history runs 7 years deep, the most recent figure standing at -$50.0 million for Q1 2026.
- In Q1 2026, EBIT fell 213.62% year-over-year to -$50.0 million; the TTM figure through Mar 2026 stood at -$102.4 million (down 4708.74% YoY), while the FY2025 annual figure was -$8.3 million, up 89.76% from the prior year.
- EBIT was -$50.0 million for Q1 2026 at Monte Rosa Therapeutics, down from -$3.8 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $44.0 million in Q1 2025 to a low of -$50.0 million in Q1 2026.
- Historically, EBIT has averaged -$23.2 million across 5 years, with a median of -$32.5 million in 2022.
- The sharpest annual moves came in 2025 and 2026: EBIT surged 226.01% in 2025, then sank 213.62% in 2026.
- A 5-year view of EBIT shows it stood at -$32.5 million in 2022, then decreased by 7.31% to -$34.9 million in 2023, then surged by 137.3% to $13.0 million in 2024, then slumped by 129.34% to -$3.8 million in 2025, then plunged by 1211.51% to -$50.0 million in 2026.
- The last three EBIT figures came in at -$50.0 million (Q1 2026), -$3.8 million (Q4 2025), and -$33.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Monte Rosa Therapeutics | 1.83 Bn | 1.15 Bn | - | -50.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.03 Mn |
| Dec 31, 2025 | -3.82 Mn |
| Sep 30, 2025 | -32.98 Mn |
| Jun 30, 2025 | -15.55 Mn |
| Mar 31, 2025 | 44.04 Mn |
| Dec 31, 2024 | 13.00 Mn |
| Sep 30, 2024 | -26.53 Mn |
| Jun 30, 2024 | -32.64 Mn |
| Mar 31, 2024 | -34.95 Mn |
| Dec 31, 2023 | -34.86 Mn |
| Sep 30, 2023 | -36.97 Mn |
| Jun 30, 2023 | -37.22 Mn |
| Mar 31, 2023 | -34.26 Mn |
| Dec 31, 2022 | -32.49 Mn |
| Sep 30, 2022 | -28.36 Mn |
| Jun 30, 2022 | -27.23 Mn |
| Mar 31, 2022 | -24.30 Mn |
| Dec 31, 2021 | -23.39 Mn |
| Sep 30, 2021 | -19.87 Mn |
| Jun 30, 2021 | -18.12 Mn |